Erika Hamilton, Chair, Executive Committee Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post on X:
“Both DB-11 (neoadj T-DXd) and DB-05 (residual disease T-DXd) will be presented back-to-back at ESMO25, Saturday October 18th 4:30pm in the presidential number 1 session.
This is the presidential session for breast cancer folks to attend! Put it on your calendars!”
More from E. Hamilton on OncoDaily.